The 10th China Obesity Science Conference Held in Beijing

The 10th China Obesity Science Conference was held in Beijing from May 10th to 11th, 2024. Experts from authoritative institutions such as the National Health Commission, the Chinese Center for Disease Control and Prevention, and the China Institute of Sports Science gathered to discuss on the topics including obesity prevalence trends.

Cost-Effectiveness Analysis of Combined Chemotherapy Regimen Containing Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis in China

Objective This study aims to estimate the cost-effectiveness of the combined chemotherapy regimen containing Bedaquiline(BR)and the conventional treatment regimen(CR,not containing Bedaquiline)for the treatment of adults with multidrug-resistant tuberculosis(MDR-TB)in China.Methods A combination of a decision tree and a Markov model was developed to estimate the cost and effects of MDR patients in BR and CR within ten years.The model parameter data were synthesized from the literature,the national TB surveillance information system,and consultation with experts.The incremental cost-effectiveness ratio(ICER)of BR vs.CR was determined.Results BR(vs.CR)had a higher sputum culture conversion rate and cure rate and prevented many premature deaths(decreased by 12.8%),thereby obtaining more quality-adjusted life years(QALYs)(increased by 2.31 years).The per capita cost in BR was as high as 138,000 yuan,roughly double that of CR.The ICER for BR was 33,700 yuan/QALY,which was lower than China's 1×per capita Gross Domestic Product(GDP)in 2020(72,400 yuan).Conclusion BR is shown to be cost effective.When the unit price of Bedaquiline reaches or falls below57.21 yuan per unit,BR is expected to be the dominant strategy in China over CR.

National Hypertension Day: Healthy Living, Ideal Blood Pressure

According to the “Report on Cardiovascular Health and Diseases in China 2022” released by the National Center for Cardiovascular Diseases, the prevalence of cardiovascular diseases in China is on the rise, with approximately 245 million people suffering from hypertension. October 8, 2023.

World Diabetes Day:Global Collaboration against Diabetes Challenges,Building a Health Defense Line

World Diabetes Day,initiated jointly by the World Health Organization and the International Diabetes Federation(IDF),is observed annually on November 14 to raise global awareness and alertness regarding diabetes.The theme in 2023 is“Understand the Risk,Understand How to Respond”.

Academic Conference on Vaccines Preventing Respiratory Infections Successfully Held in Beijing

The autumn season marks the peak incidence of respiratory diseases.In order to further enhance the prevention and control of respiratory infectious diseases in China and safeguard public health,the Academic Conference on Vaccines Preventing Respiratory Infections,organized by the Chinese Preventive Medicine Association(CPMA).

端粒酶、MUC1和STAT6在不典型子宫内膜增生癌变过程中的表达

目的探讨不典型子宫内膜增生癌变过程中端粒酶、黏蛋白(MUCl)和信号转导、转录活化因子6(signal transducers and activators of transcription,STATs)免疫组化的表达规律及临床意义。方法收集手术及刮宫标本220例,其中正常子宫内膜40例,子宫内膜轻、中、重度不典型增生各40例,子宫内膜样腺癌60例。应用免疫组化检测方法,检测上述标本中端粒酶、MUC1和STAT6的表达情况,总结各组的表达规律及特点。结果端粒酶、MUC1和STAT6三者在子宫内膜样腺癌及重度不典型增生的表达均明显高于正常子宫内膜,差异有统计学意义(P<0.05);端粒酶和MUC1在子宫内膜样腺癌的表达明显高于轻度、中度不典型增生,差异有统计学意义(P<0.05);端粒酶在重度和轻度不典型增生两者之间表达差异具有统计学意义(P<0.05);但不同程度不典型增生及子宫内膜样腺癌中STAT6的表达两两对比差异无统计学意义(P>0.05);端粒酶、MUC1和STAT6在重度不典型增生和子宫内膜样腺癌中的表达差异均无统计学意义(P>0.05)。结论在同等程度的子宫内膜不典型增生中,端粒酶、MUC1和STAT6三者联合检测,表达阳性或者阳性程度进行性加强的病例可能提示其进展为更重的不典型增生乃至癌变的潜能更大,对临床早期诊断及预后判断有一定的指导意义。